The prevalence of type 2 diabetes mellitus continues to increase rapidly. Persons with diabetes face a 2-fold greater absolute risk of cardiovascular disease (CVD) than those without diabetes. Many diabetic patients die before reaching the hospital after a cardiovascular event. Use of statin therapy for intensive control of diabetic dyslipidemia has produced relative reductions in CVD risk of about 25% in randomized, controlled clinical trials. This is true even though low-density lipoprotein cholesterol, the primary target of statin therapy, might not be markedly elevated in diabetic patients. Most patients with diabetes or diabetes plus established CVD warrant intensive statin therapy. Statin therapy has the ability to achieve low-density lipoprotein cholesterol goals recommended in treatment guidelines. Alone or in combination with an additional lipid-lowering drug, statins may also improve triglyceride and high-density lipoprotein cholesterol abnormalities in patients with diabetes.
Get full access to this article
View all access options for this article.
References
1.
Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.
2.
Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
3.
Lorenzo C., Williams K., Hunt KJ, Haffner SMThe National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30:8-13.
4.
Ford ES, Giles WH, Mokdad AHIncreasing prevalence of the metabolic syndrome among U.S. adults . Diabetes Care. 2004;27:2444-2449.
5.
Fox CS, Coady S., Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA. 2004;292:2495-2499.
6.
Gu K., Cowie CC, Harris MIDiabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291-1297.
7.
Keech A., Colquhoun D., Best J., et al, for the LIPID Study Group.Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003;26:2713-2721.
8.
American Diabetes Association.Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27(suppl 1):S68-S71.
9.
Lipitor (atorvastatin calcium) [prescribing information]. New York: Pfizer, Inc; December 2006.
10.
Lescol (fluvastatin sodium) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; April 2006.
Heart Protection StudyCollaborative Group.MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
16.
Colhoun HM, Betteridge DJ, Durrington PN, et al, on behalf of the CARDS investigators.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
17.
Vijan S., Hayward RAPharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med . 2004;140:650-658.
18.
Haffner SM, Lehto S., Rönnemaa T., Pyörälä K., Laakso M.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
19.
Miettinen H. , Lehto S., Salomaa V., et al, for the FINMONICA Myocardial Infarction Register Study Group.Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care. 1998;21:69-75.
20.
Grundy SM, Cleeman JI, Bairey Merz CN, et al, for the Coordinating Committee of the National Cholesterol Education Program.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
21.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Third Report of the National Cholesterol Education Program (NCEP) Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III): final report . Circulation. 2002;106:3143-3421.
22.
Gaede P., Vedel P., Larsen N., Jensen GVH, Parving H-H., Pedersen O.Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
23.
Turner RC, Millns H., Neil HAW, et al, for the United Kingdom Prospective Diabetes Study Group.Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ. 1998;316:823-828.
24.
Pyörälä K., Pedersen TR, Kjekshus J., Faergeman O., Olsson AG, Thorgeirsson G.; Scandinavian Simvastatin SurvivalStudy (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
25.
Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care. 2007;30:162-172.
26.
Krentz AJLipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab. 2003 ;5(suppl 1):S19-S27.
Kathiresan S., Otvos JD, Sullivan LM, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006;113:20-29.
29.
Kawamoto R. , Tomita H., Oka Y., Kodama A., Kamitani A.Metabolic syndrome amplifies the LDL-cholesterol associated increases in carotid atherosclerosis . Intern Med . 2005;44:1232-1238.
30.
Sniderman AD , Scantlebury T., Cianflone K.Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001;135:447-459.
31.
Smith SC Jr, Allen J., Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006;113: 2363-2372.
32.
Betteridge D., Gibson M.Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of the ANDROMEDA study. Atherosclerosis. 2004;5:107-108. Abstract M.464.
33.
The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group.The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care. 2001; 24:1335-1341.
34.
Jones PH, Davidson MH, Stein EA, et al, for the STELLAR Study Group.Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92:152-160.
35.
Leiter LA, Rosenson RS, Stein E., et al, on behalf of the POLARIS study investigators.Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis. 2007;194:e154-e164.
36.
Goldberg RB , Mellies MJ, Sacks FM, et al, for the CARE Investigators.Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 1998;98:2513-2519.
37.
Shepherd J. , Barter P., Carmena R., et al, for the Treating to New Targets Investigators.Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220-1226.
38.
Pedersen TR , Faergeman O., Kastelein JJP, et al, for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.
39.
Cannon CP, Braunwald E., McCabe CH, et al, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators.Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 ;350:1495-1504.
40.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
41.
Sever PS, Dahlöf B., Poulter NR, et al, for the ASCOT Investigators.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
42.
Downs JR, Clearfield M., Weis S., et al, for the AFCAPS/TexCAPS Research Group.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCaps . JAMA. 1998;279:1615-1622.
43.
Knopp RH, D'Emden M., Smilde JG, Pocock SJ, on behalf of the ASPEN Study Group.Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care. 2006;29:1478-1485.
44.
LaRosa JC, Grundy SM, Waters DD, et al, for the Treating to New Targets (TNT) Investigators.Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
45.
Snow V., Aronson MD, Hornbake ER, Mottur-Pilson C., Weiss KB, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians.Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004;140:644-649.
46.
Garg A.Statins for all patients with type 2 diabetes: not so soon. Lancet. 2004;364:641-642.
47.
Wolffenbuttel BHR , Franken AAM, Vincent HH, on behalf of the Dutch CORALL Study Group.Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes: CORALL study . J Intern Med. 2005 ;257:531-539.
48.
Berne C., Siewert-Delle A.; URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol. 2005 ;4:7.
49.
Durrington PN, Tuomilehto J., Hamann A., Kallend D., Smith K.Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract. 2004;64:137-151.
50.
Bergman AJ, Murphy G., Burke J., et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol. 2004;44:1054-1062.
51.
Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulous AGAtorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care . 2002;25:1198-1202.
52.
Goldberg RB , Guyton JR, Mazzone T., et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc. 2006;81:1579-1588.
53.
Denke M., Pearson T., McBride P., Gazzara RA, Brady WE, Tershakovec AMEzetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res. 2006;3:93-102.
54.
Ballantyne CM, Weiss R., Moccetti T., et al, for the EXPLORER Study Investigators.Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99:673-680.
55.
Rätz Bravo AE, Tchambaz L., Krähenbühl-Melcher A., Hess L., Schlienger RG, Krähenbühl S.Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf. 2005;28:263-275.
56.
Scheen AJDrug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf. 2005;28:601-631.
57.
Davidson MHStatin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006;5:145-156.
